Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2022

Open Access 01-12-2022 | Pulmonary Hypertension | Research

Use of machine learning models to predict prognosis of combined pulmonary fibrosis and emphysema in a Chinese population

Authors: Qing Liu, Di Sun, Yu Wang, Pengfei Li, Tianci Jiang, Lingling Dai, Mengjie Duo, Ruhao Wu, Zhe Cheng

Published in: BMC Pulmonary Medicine | Issue 1/2022

Login to get access

Abstract

Background

Combined pulmonary fibrosis and emphysema (CPFE) is a novel clinical entity with a poor prognosis. This study aimed to develop a clinical nomogram model to predict the 1-, 2- and 3-year mortality of patients with CPFE by using the machine learning approach, and to validate the predictive ability of the interstitial lung disease-gender-age-lung physiology (ILD-GAP) model in CPFE.

Methods

The data of CPFE patients from January 2015 to October 2021 who met the inclusion criteria were retrospectively collected. We utilized LASSO regression and multivariable Cox regression analysis to identify the variables associated with the prognosis of CPFE and generate a nomogram. The Harrell's C index, the calibration curve and the area under the receiver operating characteristic (ROC) curve (AUC) were used to evaluate the performance of the nomogram. Then, we performed likelihood ratio test, net reclassification improvement (NRI), integrated discrimination improvement (IDI) and decision curve analysis (DCA) to compare the performance of the nomogram with that of the ILD-GAP model.

Results

A total of 184 patients with CPFE were enrolled. During the follow-up, 90 patients died. After screening out, diffusing lung capacity for carbon monoxide (DLCO), right ventricular diameter (RVD), C-reactive protein (CRP), and globulin were found to be associated with the prognosis of CPFE. The nomogram was then developed by incorporating the above five variables, and it showed a good performance, with a Harrell's C index of 0.757 and an AUC of 0.800 (95% CI 0.736–0.863). Moreover, the calibration plot of the nomogram showed good concordance between the prediction probabilities and the actual observations. The nomogram also improved the discrimination ability of the ILD-GAP model compared to that of the ILD-GAP model alone, and this was substantiated by the likelihood ratio test, NRI and IDI. The significant clinical utility of the nomogram was demonstrated by DCA.

Conclusion

Age, DLCO, RVD, CRP and globulin were identified as being significantly associated with the prognosis of CPFE in our cohort. The nomogram incorporating the 5 variables showed good performance in predicting the mortality of CPFE. In addition, although the nomogram was superior to the ILD-GAP model in the present cohort, further validation is needed to determine the clinical utility of the nomogram.
Literature
1.
go back to reference Papaioannou AI, Kostikas K, Manali ED, Papadaki G, Roussou A, Kolilekas L, Borie R, Bouros D, Papiris SA. Combined pulmonary fibrosis and emphysema: the many aspects of a cohabitation contract. Respir Med. 2016;117:14–26.PubMedCrossRef Papaioannou AI, Kostikas K, Manali ED, Papadaki G, Roussou A, Kolilekas L, Borie R, Bouros D, Papiris SA. Combined pulmonary fibrosis and emphysema: the many aspects of a cohabitation contract. Respir Med. 2016;117:14–26.PubMedCrossRef
3.
go back to reference Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586–93.PubMedCrossRef Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586–93.PubMedCrossRef
4.
go back to reference Lee CH, Kim HJ, Park CM, Lim KY, Lee JY, Kim DJ, Yeon JH, Hwang SS, Kim DK, Lee SM, et al. The impact of combined pulmonary fibrosis and emphysema on mortality. Int J Tuberc Lung Dis. 2011;15(8):1111–6.PubMedCrossRef Lee CH, Kim HJ, Park CM, Lim KY, Lee JY, Kim DJ, Yeon JH, Hwang SS, Kim DK, Lee SM, et al. The impact of combined pulmonary fibrosis and emphysema on mortality. Int J Tuberc Lung Dis. 2011;15(8):1111–6.PubMedCrossRef
5.
go back to reference Jiang CG, Fu Q, Zheng CM. Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone. Ther Adv Respir Dis. 2019;13:1753466619888119.PubMedPubMedCentralCrossRef Jiang CG, Fu Q, Zheng CM. Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone. Ther Adv Respir Dis. 2019;13:1753466619888119.PubMedPubMedCentralCrossRef
6.
go back to reference Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE Jr, Ryu J, Collard HR. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144(1):234–40.PubMedCrossRef Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE Jr, Ryu J, Collard HR. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144(1):234–40.PubMedCrossRef
7.
8.
go back to reference Mitchell PD, Das JP, Murphy DJ, Keane MP, Donnelly SC, Dodd JD, Butler MW. Idiopathic pulmonary fibrosis with emphysema: evidence of synergy among emphysema and idiopathic pulmonary fibrosis in smokers. Respir Care. 2015;60(2):259–68.PubMedCrossRef Mitchell PD, Das JP, Murphy DJ, Keane MP, Donnelly SC, Dodd JD, Butler MW. Idiopathic pulmonary fibrosis with emphysema: evidence of synergy among emphysema and idiopathic pulmonary fibrosis in smokers. Respir Care. 2015;60(2):259–68.PubMedCrossRef
9.
go back to reference Jankowich MD, Polsky M, Klein M, Rounds S. Heterogeneity in combined pulmonary fibrosis and emphysema. Respiration. 2008;75(4):411–7.PubMedCrossRef Jankowich MD, Polsky M, Klein M, Rounds S. Heterogeneity in combined pulmonary fibrosis and emphysema. Respiration. 2008;75(4):411–7.PubMedCrossRef
10.
go back to reference Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723–8.PubMedCrossRef Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723–8.PubMedCrossRef
11.
go back to reference Koo BS, Park KY, Lee HJ, Kim HJ, Ahn HS, Yim SY, Jun JB. Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis. Arthritis Res Ther. 2021;23(1):100.PubMedPubMedCentralCrossRef Koo BS, Park KY, Lee HJ, Kim HJ, Ahn HS, Yim SY, Jun JB. Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis. Arthritis Res Ther. 2021;23(1):100.PubMedPubMedCentralCrossRef
12.
go back to reference van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55.PubMedCrossRef van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55.PubMedCrossRef
13.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8.PubMedCrossRef Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8.PubMedCrossRef
14.
go back to reference Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruch PA, Rockette H, Feldman BM, Huber AM, Hansen P, et al. 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. Rheumatology (Oxford). 2017;56(11):1884–93.CrossRef Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruch PA, Rockette H, Feldman BM, Huber AM, Hansen P, et al. 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. Rheumatology (Oxford). 2017;56(11):1884–93.CrossRef
15.
go back to reference Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16.PubMedCrossRef Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16.PubMedCrossRef
16.
go back to reference Calandrino RL, McAuliffe KJ, Dolmage LE, Trivedi ER. Synthesis of the C3 and C1 constitutional isomers of trifluorosubphthalocyanine and their fluorescence within MDA-MB-231 breast tumor cells. Molecules. 2019;24(21):3832.CrossRef Calandrino RL, McAuliffe KJ, Dolmage LE, Trivedi ER. Synthesis of the C3 and C1 constitutional isomers of trifluorosubphthalocyanine and their fluorescence within MDA-MB-231 breast tumor cells. Molecules. 2019;24(21):3832.CrossRef
17.
go back to reference Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–9.PubMedCrossRef Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–9.PubMedCrossRef
18.
go back to reference Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366–83.PubMedCrossRef Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366–83.PubMedCrossRef
19.
go back to reference Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S. The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun. 2014;48–49:50–2.PubMedCrossRef Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S. The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun. 2014;48–49:50–2.PubMedCrossRef
20.
go back to reference Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75.PubMedCrossRef Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75.PubMedCrossRef
21.
go back to reference Douglas PS, Khandheria B, Stainback RF, Weissman NJ, Brindis RG, Patel MR, Alpert JS, Fitzgerald D, et al. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance. Endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Soc Echocardiogr. 2007;20(7):787–805.PubMedCrossRef Douglas PS, Khandheria B, Stainback RF, Weissman NJ, Brindis RG, Patel MR, Alpert JS, Fitzgerald D, et al. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance. Endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Soc Echocardiogr. 2007;20(7):787–805.PubMedCrossRef
22.
go back to reference Malik N, Win S, James CA, Kutty S, Mukherjee M, Gilotra NA, Tichnell C, Murray B, Agafonova J, Tandri H, et al. Right ventricular strain predicts structural disease progression in patients with arrhythmogenic right ventricular cardiomyopathy. J Am Heart Assoc. 2020;9(7): e015016.PubMedPubMedCentralCrossRef Malik N, Win S, James CA, Kutty S, Mukherjee M, Gilotra NA, Tichnell C, Murray B, Agafonova J, Tandri H, et al. Right ventricular strain predicts structural disease progression in patients with arrhythmogenic right ventricular cardiomyopathy. J Am Heart Assoc. 2020;9(7): e015016.PubMedPubMedCentralCrossRef
23.
go back to reference Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697–722.PubMedCrossRef Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697–722.PubMedCrossRef
25.
go back to reference Jin C, Cao J, Cai Y, Wang L, Liu K, Shen W, Hu J. A nomogram for predicting the risk of invasive pulmonary adenocarcinoma for patients with solitary peripheral subsolid nodules. J Thorac Cardiovasc Surg. 2017;153(2):462–9.PubMedCrossRef Jin C, Cao J, Cai Y, Wang L, Liu K, Shen W, Hu J. A nomogram for predicting the risk of invasive pulmonary adenocarcinoma for patients with solitary peripheral subsolid nodules. J Thorac Cardiovasc Surg. 2017;153(2):462–9.PubMedCrossRef
26.
go back to reference Kwiatkowska S. IPF and CPFE—the two different entities or two different presentations of the same disease? Adv Respir Med. 2018;86(1):23–6.PubMedCrossRef Kwiatkowska S. IPF and CPFE—the two different entities or two different presentations of the same disease? Adv Respir Med. 2018;86(1):23–6.PubMedCrossRef
27.
go back to reference Zantah M, Dotan Y, Dass C, Zhao H, Marchetti N, Criner GJ. Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema. Respir Res. 2020;21(1):164.PubMedPubMedCentralCrossRef Zantah M, Dotan Y, Dass C, Zhao H, Marchetti N, Criner GJ. Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema. Respir Res. 2020;21(1):164.PubMedPubMedCentralCrossRef
28.
go back to reference Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385–95.PubMedCrossRef Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385–95.PubMedCrossRef
29.
go back to reference Ajana S, Acar N, Bretillon L, Hejblum BP, Jacqmin-Gadda H, Delcourt C, for the BLISAR Study Group. Benefits of dimension reduction in penalized regression methods for high-dimensional grouped data: a case study in low sample size. Bioinformatics. 2019;35(19):3628–34.PubMedCrossRef Ajana S, Acar N, Bretillon L, Hejblum BP, Jacqmin-Gadda H, Delcourt C, for the BLISAR Study Group. Benefits of dimension reduction in penalized regression methods for high-dimensional grouped data: a case study in low sample size. Bioinformatics. 2019;35(19):3628–34.PubMedCrossRef
30.
go back to reference Kam MLW, Li HH, Tan YH, Low SY. Validation of the ILD-GAP model and a local nomogram in a Singaporean cohort. Respiration. 2019;98(5):383–90.PubMedCrossRef Kam MLW, Li HH, Tan YH, Low SY. Validation of the ILD-GAP model and a local nomogram in a Singaporean cohort. Respiration. 2019;98(5):383–90.PubMedCrossRef
31.
go back to reference Awano N, Inomata M, Ikushima S, Yamada D, Hotta M, Tsukuda S, Kumasaka T, Takemura T, Eishi Y. Histological analysis of vasculopathy associated with pulmonary hypertension in combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis or emphysema alone. Histopathology. 2017;70(6):896–905.PubMedCrossRef Awano N, Inomata M, Ikushima S, Yamada D, Hotta M, Tsukuda S, Kumasaka T, Takemura T, Eishi Y. Histological analysis of vasculopathy associated with pulmonary hypertension in combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis or emphysema alone. Histopathology. 2017;70(6):896–905.PubMedCrossRef
32.
go back to reference Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galie N, Ghio S, Gibbs S, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109-116.PubMedCrossRef Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galie N, Ghio S, Gibbs S, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109-116.PubMedCrossRef
33.
go back to reference Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, Cordier JF. Germ"O"P: pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35(1):105–11.PubMedCrossRef Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, Cordier JF. Germ"O"P: pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35(1):105–11.PubMedCrossRef
34.
go back to reference Toubi E, Vadasz Z. Innate immune-responses and their role in driving autoimmunity. Autoimmun Rev. 2019;18(3):306–11.PubMedCrossRef Toubi E, Vadasz Z. Innate immune-responses and their role in driving autoimmunity. Autoimmun Rev. 2019;18(3):306–11.PubMedCrossRef
35.
go back to reference Gimeno D, Delclos GL, Ferrie JE, De Vogli R, Elovainio M, Marmot MG, Kivimaki M. Association of CRP and IL-6 with lung function in a middle-aged population initially free from self-reported respiratory problems: the Whitehall II study. Eur J Epidemiol. 2011;26(2):135–44.PubMedPubMedCentralCrossRef Gimeno D, Delclos GL, Ferrie JE, De Vogli R, Elovainio M, Marmot MG, Kivimaki M. Association of CRP and IL-6 with lung function in a middle-aged population initially free from self-reported respiratory problems: the Whitehall II study. Eur J Epidemiol. 2011;26(2):135–44.PubMedPubMedCentralCrossRef
36.
go back to reference Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. 2018;70:61–75.PubMedCrossRef Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. 2018;70:61–75.PubMedCrossRef
37.
go back to reference Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, Lee JS, Bonella F, Bouros D, Hoffmann-Vold AM, Crestani B, Matteson EL. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis. 2021;80(2):143–50.PubMedCrossRef Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, Lee JS, Bonella F, Bouros D, Hoffmann-Vold AM, Crestani B, Matteson EL. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis. 2021;80(2):143–50.PubMedCrossRef
38.
go back to reference Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Investig. 2021;131(2):e143226.PubMedCentralCrossRef Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Investig. 2021;131(2):e143226.PubMedCentralCrossRef
39.
go back to reference Enocsson H, Karlsson J, Li HY, Wu Y, Kushner I, Wettero J, Sjowall C. The complex role of C-reactive protein in systemic lupus erythematosus. J Clin Med. 2021;10(24):5837.PubMedPubMedCentralCrossRef Enocsson H, Karlsson J, Li HY, Wu Y, Kushner I, Wettero J, Sjowall C. The complex role of C-reactive protein in systemic lupus erythematosus. J Clin Med. 2021;10(24):5837.PubMedPubMedCentralCrossRef
40.
41.
go back to reference Cottin V, Nunes H, Mouthon L, Gamondes D, Lazor R, Hachulla E, Revel D, Valeyre D, Cordier JF. Groupe d’Etudes et de Recherche sur les Maladies "Orphelines P: combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum. 2011;63(1):295–304.PubMedCrossRef Cottin V, Nunes H, Mouthon L, Gamondes D, Lazor R, Hachulla E, Revel D, Valeyre D, Cordier JF. Groupe d’Etudes et de Recherche sur les Maladies "Orphelines P: combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum. 2011;63(1):295–304.PubMedCrossRef
42.
go back to reference Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350: g7594.PubMedCrossRef Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350: g7594.PubMedCrossRef
43.
go back to reference Park SY. Nomogram: an analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg. 2018;155(4):1793.PubMedCrossRef Park SY. Nomogram: an analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg. 2018;155(4):1793.PubMedCrossRef
44.
go back to reference Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, McGinn T, Guyatt G. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–84.PubMedCrossRef Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, McGinn T, Guyatt G. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–84.PubMedCrossRef
45.
go back to reference Lee SH, Park JS, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, Park CS, Park SW, Jeong SH, et al. Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study. Sci Rep. 2018;8(1):4784.PubMedPubMedCentralCrossRef Lee SH, Park JS, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, Park CS, Park SW, Jeong SH, et al. Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study. Sci Rep. 2018;8(1):4784.PubMedPubMedCentralCrossRef
46.
go back to reference Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.PubMedPubMedCentralCrossRef Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.PubMedPubMedCentralCrossRef
47.
go back to reference Timmins SC, Diba C, Farrow CE, Schoeffel RE, Berend N, Salome CM, King GG. The relationship between airflow obstruction, emphysema extent, and small airways function in COPD. Chest. 2012;142(2):312–9.PubMedCrossRef Timmins SC, Diba C, Farrow CE, Schoeffel RE, Berend N, Salome CM, King GG. The relationship between airflow obstruction, emphysema extent, and small airways function in COPD. Chest. 2012;142(2):312–9.PubMedCrossRef
48.
go back to reference Suzuki M, Kawata N, Abe M, Yokota H, Anazawa R, Matsuura Y, Ikari J, Matsuoka S, Tsushima K, Tatsumi K. Objective quantitative multidetector computed tomography assessments in patients with combined pulmonary fibrosis with emphysema: relationship with pulmonary function and clinical events. PLoS ONE. 2020;15(9): e0239066.PubMedPubMedCentralCrossRef Suzuki M, Kawata N, Abe M, Yokota H, Anazawa R, Matsuura Y, Ikari J, Matsuoka S, Tsushima K, Tatsumi K. Objective quantitative multidetector computed tomography assessments in patients with combined pulmonary fibrosis with emphysema: relationship with pulmonary function and clinical events. PLoS ONE. 2020;15(9): e0239066.PubMedPubMedCentralCrossRef
49.
go back to reference Feldhaus FW, Theilig DC, Hubner RH, Kuhnigk JM, Neumann K, Doellinger F. Quantitative CT analysis in patients with pulmonary emphysema: is lung function influenced by concomitant unspecific pulmonary fibrosis? Int J Chron Obstruct Pulmon Dis. 2019;14:1583–93.PubMedPubMedCentralCrossRef Feldhaus FW, Theilig DC, Hubner RH, Kuhnigk JM, Neumann K, Doellinger F. Quantitative CT analysis in patients with pulmonary emphysema: is lung function influenced by concomitant unspecific pulmonary fibrosis? Int J Chron Obstruct Pulmon Dis. 2019;14:1583–93.PubMedPubMedCentralCrossRef
50.
go back to reference Hammerstingl C, Schueler R, Bors L, Momcilovic D, Pabst S, Nickenig G, Skowasch D. Diagnostic value of echocardiography in the diagnosis of pulmonary hypertension. PLoS ONE. 2012;7(6): e38519.PubMedPubMedCentralCrossRef Hammerstingl C, Schueler R, Bors L, Momcilovic D, Pabst S, Nickenig G, Skowasch D. Diagnostic value of echocardiography in the diagnosis of pulmonary hypertension. PLoS ONE. 2012;7(6): e38519.PubMedPubMedCentralCrossRef
Metadata
Title
Use of machine learning models to predict prognosis of combined pulmonary fibrosis and emphysema in a Chinese population
Authors
Qing Liu
Di Sun
Yu Wang
Pengfei Li
Tianci Jiang
Lingling Dai
Mengjie Duo
Ruhao Wu
Zhe Cheng
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2022
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-022-02124-6

Other articles of this Issue 1/2022

BMC Pulmonary Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine